Vutrisiran
| Clinical data | |
|---|---|
| Trade names | Amvuttra |
| Other names | ALN-65492 |
| License data |
|
| Routes of administration | Subcutaneous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank |
|
| UNII |
|
| KEGG | |
Vutrisiran, sold under the brand name Amvuttra, is a medication used for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.[1]
Vutrisiran was approved for medical use in the United States in June 2022.[1]
Vutrisiran is the international nonproprietary name (INN).[3]
History
The FDA granted the application for vutrisiran orphan drug designation.[4]
References
- ^ a b c "Alnylam Announces FDA Approval of Amvuttra (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults". Alnylam. 13 June 2022. Archived from the original on 14 June 2022. Retrieved 14 June 2022 – via Business Wire.
- ^ "Archived copy" (PDF). Archived (PDF) from the original on 14 June 2022. Retrieved 14 June 2022.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.
- ^ "Vutrisiran Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 25 May 2018. Retrieved 14 June 2022.
External links
- "Vutrisiran". Drug Information Portal. U.S. National Library of Medicine.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |